ISG15 antibody has been tested by ELISA and Western blot analysis to assure specificity and reactivity. Recommended dilution range for Western blot analysis is 1:1,000 ~ 2,000. Recommended starting dilution is 1:1,000.
Anti-human ISG15 mAb is derived from hybridization of mouse SP2/0 myeloma cells with spleen cells from BALB/c mice immunized with recombinant human ISG15 amino acids 1-157 purified from E. coli.
ISG15 ubiquitin-like Modifier is conjugated to the intracellular target proteins after IFN-alpha or IFN-beta stimulation. ISG15 enzymatic pathway is partially distinct from that of ubiquitin, differing in substrate specificity and interaction with ligating enzymes. ISG15 conjugation pathway uses a dedicated E1 enzyme, but seems to converge with the ub conjugation pathway at the level of a specific E2 enzyme. ISG15 protein targets include STAT1, SERPINA 3G/SPI2A, JAK1, MAPK3/ERK1, PLCG1, EIF2AK2/PKR, MX1/MXA, and RIG-1. Deconjugated by USP18/UBP43 shows specific chemotactic activity towards neutrophils and activates them to induce release of eosinophil chemotactic factors. ISG15 serves as a trans-acting binding factor directing the association of ligated target proteins to intermediate filaments. ISG15 plays a role in autocrine, paracrine and endocrine mechanisms, as in cell-to-cell signaling, possibly partly by inducing ifn-gamma secretion by monocytes and macrophages. ISG15 displays a
[1] Ritchie, K.J. and Zhang, D.E. (2004) Semin. Cell Dev. Biol. 15, 237-246.
[2] Korant, B.D. et al. (1984) J. Biol. Chem. 259, 14835-14839.
[3] Haas, A.L. et al. (1987) J. Biol. Chem. 262, 11315-11323.
[4] Knight, E. and Cordova, B. (1991) J. Immunol. 146, 2280-2284.
[5] D'Cunha, J. et al. (1996) Proc. Natl. Acad. Sci. USA 93, 211-215.
[6] Loeb, K.R. and Haas, A.L. (1992) J. Biol. Chem. 267, 7806-7813.
[7] Zhao, C. et al. (2005) Proc. Natl. Acad. Sci. USA 102, 10200-10205.
[8] Malakhov, M.P. et al. (2002) J. Biol. Chem. 277, 9976-9981.
[9] Malakhov, M.P. et al. (2003) J. Biol. Chem. 278, 16608-16613.
[10] Hamerman, J.A. et al. (2002) J. Immunol. 168, 2415-2423.